MedTrace Logo

Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer

NCT07687875 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-07-10

No results posted yet for this study

Summary

A Phase I clinical trial that will investigate the safety and tolerability of combining the modified vaccinia virus BT-001 with systemic pembrolizumab in patients with localised pMMR rectal cancer

Conditions

  • Rectal Cancer Patients

Interventions

DRUG

BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody)

Two doses of BT-001 delivered by intra-tumoural injection followed by one systemic dose of pembrolizumab

Sponsors & Collaborators

  • Transgene

    collaborator INDUSTRY

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Henry Smith

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-17
Primary Completion
2028-12-31
Completion
2033-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07687875 on ClinicalTrials.gov